Bicara Reports Substantial Enrollment in FORTIFI-HN01 Cancer Trial

Your call?🐂 Bullish🐻 Bearish

Bicara expects topline results from an interim analysis in mid-2027 and says its $442.3 million in cash, cash equivalents and marketable securities can fund operations into the first half of 2029.